This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.
This section of the website is for UK healthcare professionals only. If you are not a healthcare professional, please click here.

SGLT-2i NICE Treatment Options

Increasing the treatment options available for adults with T2DM

Prescribing Information

Length: 01:32

In this short video, Prof John Wilding will give you a quick update on the role of SGLT-2 inhibitors in the management of people with T2DM. Prof Wilding also explores the most recently available SGLT-2 inhibitor Steglatro and its NICE recommendations.

John Wilding leads Clinical Research into Obesity, Diabetes and Endocrinology at the University of Liverpool. He leads specialist services for severe obesity at University Hospital Aintree – designated a Centre for Obesity Management by the UK and European Associations for the Study of Obesity. John’s research team focusses on developing new treatments and strategies to reduce the burden of diabetes and obesity-related disease.

Interested in learning how STEGLATRO can support adults with T2DM?

Supporting documentation

STEGLATRO® (ertugliflozin) 5 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

STEGLATRO® (ertugliflozin) 15 mg
Prescribing Information | Summary of Product Characteristics | Patient Information Leaflet

GB-DIA-00535 | Date of Preparation: July 2019